目的探讨鱼油脂肪乳联合替吉奥+奥沙利铂(SOX方案)治疗进展期胃癌的临床疗效和不良反应。方法 70例进展期胃癌的患者随机分为试验组和对照组,每组35例。试验组患者采用鱼油脂肪乳联合SOX方案新辅助化疗,对照组患者单用奥沙利铂+希罗达(XELOX方案)新辅助化疗,2个周期后比较两组患者的临床疗效和化疗后不良反应。结果试验组和对照组患者的治疗有效率分别为65.7%和48.6%,两组比较差异有统计学意义(P<0.05)。试验组患者在卡氏评分和不良反应方面均优于对照组,差异有统计学意义(P<0.05)。结论鱼油脂肪乳联合SOX方案治疗进展期胃癌安全可靠,提高了临床疗效和患者的生存质量,不良反应较轻。 Objective To investigate the clinical efficacy and side effects of fish oil fat emulsion combined with tioguanxide + oxaliplatin (SOX) in the treatment of advanced gastric cancer. Methods 70 patients with advanced gastric cancer were randomly divided into experimental group and control group, 35 cases in each group. Patients in the test group received neoadjuvant chemotherapy with fish oil fat emulsion combined with SOX, and patients in the control group received neoadjuvant chemotherapy alone with oxaliplatin plus Xeloda (XELOX regimen). The clinical efficacy and post-chemotherapy adverse outcomes were compared between the two groups after 2 cycles reaction. Results The effective rates of treatment in trial group and control group were 65.7% and 48.6%, respectively, with significant difference between the two groups (P <0.05). The patients in the test group were better than the control group in Karnofsky scores and adverse reactions, the difference was statistically significant (P <0.05). Conclusion The combination of fish oil fat emulsion and SOX regimen in the treatment of advanced gastric cancer is safe and reliable, improving clinical efficacy and quality of life of patients with mild adverse reactions.